Status:

UNKNOWN

Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders

Lead Sponsor:

University of Roma La Sapienza

Conditions:

Cushing Syndrome

Adrenal Insufficiency

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by altera...

Detailed Description

This is an intervention, prospective, multicentric study. Enrolled patients will undergo 4 visits: * Adrenal insufficiency (AI) patients: patients affected by primary or secondary adrenal insufficie...

Eligibility Criteria

Inclusion

  • Primary or secondary chronic adrenal insufficiency, previously or newly diagnosed.
  • ACTH-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating).
  • Signed informed consent to participate in the study.

Exclusion

  • \- acute adrenal insufficiency;
  • clinical or laboratory signs of significant respiratory, hepatobiliary, or pancreatic disease;
  • pregnancy;
  • severe infections, surgery, trauma requiring hospitalization within 3 months before study entry;
  • any active blood or rheumatic disorders, and active liver disease in the previous 5 years;
  • clinically significant chronic kidney disease;
  • severe psychiatric diseases;
  • history of neoplasms in the last 5 years (except for adrenal or pituitary adenoma in Cushing Syndrome, pituitary adenoma or related neolpasms in secondary adrenal insufficiency);
  • heart disease with a class III or class IV functional capacity;
  • BMI greater than 40 kg/m²;
  • use of medication that interferes with cortisol metabolism within 1 month before study entry;
  • treatment with systemic Glucocorticoid (GC) therapy other than hydrocortisone (HC), or cortisone acetate (CA);
  • alcoholism and/or drug addictions;
  • night-shift workers;
  • use of melatonin, antipsychotic medications, estroprogestinic preparations

Key Trial Info

Start Date :

July 4 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2023

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT04374721

Start Date

July 4 2018

End Date

December 1 2023

Last Update

November 30 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Experimental Medicine, "Sapienza" University of Rome

Roma, Italy, 00161